Semaglutide and tirzepatide for obesity: A summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council
Authors:
- 1 May 2026
- journal article
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 32 (5) , 631-636
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trialThe Lancet Diabetes & Endocrinology, 2024
- Obesity Management in AdultsJAMA, 2023
- Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trialNature Medicine, 2023
- AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With ObesityGastroenterology, 2022
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trialNature Medicine, 2022
- Tirzepatide Once Weekly for the Treatment of ObesityNew England Journal of Medicine, 2022
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without DiabetesJAMA, 2022
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or ObesityJAMA, 2021
- Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine, 2021
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2019